Tissue engineering scaffolds are often made from the decellularization of tissues. The decellularization of tissues caused by prolonged contact with aqueous detergents might harm the microstructure and leave cytotoxic residues. In this research, we developed a new technique to use supercritical carbon dioxide (Sc-CO ₂ )-based decellularization for porcine nerve tissue. The effect of decellularization was analyzed by histological examination, including Hematoxylin and Eosin, Masson's Trichrome staining, and 4′,6-diamidino-2-phenylindole staining. Moreover, biochemical analysis of the decellularized tissues was also performed by measuring DNA content, amount of collagen, and glycosaminoglycans (GAGs) after decellularization. The results showed that the tissue structure was preserved, cells were removed, and the essential components of extracellular matrix, such as collagen fibers, elastin fibers, and GAG fibers, remained after decellularization. In addition, the DNA content was decreased compared with native tissue, and the concentration of collagen and GAGs in the decellularized nerve tissue was the same as in native tissue. The in vivo experiment in the rat model showed that after 6 months of decellularized nerve implantation, the sciatic function index was confirmed to recover in decellularized nerve. Morphological analysis displayed a range of infiltrated cells in the decellularized nerve, similar to that in native tissue, and the number of Schwann cells that play essential for motor function and sensory in the decellularized nerve was confirmed. These findings indicate that tissue decellularization using Sc-CO ₂ has been successfully used in tissue engineering.

One of the most notable signs of an aging face is the nasolabial folds (NLFs), which often diminish emotional well-being and self-confidence. To address this concern, many people seek solutions to improve their appearance, often turning to fillers. The ULTRACOL100 device, a tissue restoration material, has been previously investigated and shown to exhibit significant efficacy in both in vitro and in vivo studies. In this research, we aim to explore the safety and effectiveness of the clinical trial of ULTRACOL100 in improving the skin in the NLF area over an 8-week observation period. Male and Female adults with nasolabial folds received two injections of ULTRACOL100, with a 4-week interval between treatments, on one side of their faces. On the other side, they received control materials (REJURAN^®, JUVELOOK^®, or HYRONT^®). The assessment of skin improvement in the nasolabial fold area for each subject took place before and four weeks after each application. Various skin parameters, such as roughness, elasticity, moisture, transparency, trans-epidermal water loss, tone, radiance, skin pore size, and skin density, were measured to evaluate the outcomes. The application of the ULTRACOL100 device significantly reduced the skin roughness, the trans-epidermal water loss, and the skin pore size and increased the skin’s elasticity and internal elasticity, as well as the skin’s moisture, transparency, skin tone, radiance, and density. This study comprehensively investigates the effectiveness and safety of the ULTRACOL100 device, comparing it with three commercial products (REJURAN^®, JUVELOOK^®, and HYRONT^®). The ULTRACOL100 device showed comparable performance in improving the appearance of the NLF area among this study subjects.

Antiviral nucleoside analogues (ANA) are newly used therapeutics acting against the hepatitis C virus (HCV). This class of drug is well known to exhibit toxicity on mitochondrial DNA (mtDNA). People who inject drugs (PWID) are particularly affected by HCV infection and cumulated mitotoxic drug exposure from HIV treatments (antiretrovirals, ARV) and other illicit drugs. This study aims to explore the impact of direct-acting antiviral (DAA) treatments on mtDNA among PWID. A total of 470 actively injecting heroin users were included. We used quantitative PCR on whole blood to determine the mitochondrial copy number per cell (MCN) and the proportion of mitochondrial DNA deletion (MDD). These parameters were assessed before and after DAA treatment. MDD was significantly increased after HCV treatment, while MCN did not differ. MDD was even greater when subjects were cotreated with ARV. In multivariate analysis, we identified that poly-exposure to DAA and daily heroin injection or regular consumption of methamphetamines were positively associated with high MCN loss while DAA and ARV treatments or methadone use were identified as risk factors for having mtDNA deletion. These observations deserve attention since they were previously associated with premature cell ageing or cell transformation and therefore call for a long-term follow-up.

People who inject drugs (PWID) are a population exposed to many genotoxicants and with a high prevalence of HCV infection. Direct-acting antiviral (DAA) regimens are now widely used to treat chronic HCV infection. Although side effects to treatment are currently rare, the long-term effects such as suspicions of de novo hepatocellular carcinoma (HCC) occurrence or HCC recurrence and cardiac defects are still up for debate. Given the structure of DAAs, the molecules have a potential mitochondrial DNA (mtDNA) genotoxicity. We have previously reported acute mtDNA toxicity of three DAA regimens among PWID with a strong impact on the rate of mtDNA deletion, less on the quantity of mtDNA copy per cell at sustained viral response at 12 weeks (SVR12). Herein, we report the mtDNA parameters nine months after drug discontinuation. We observed that the percentage of the deleted mtDNA genome increased over time. No exposure to any other genotoxicants during this period was associated with a high deletion percentage, suggesting that the replicative advantage of the deleted molecules outweighed their elimination processes. Such observation calls for longer-term follow-up and may contribute to the molecular basis of subclinical side effects of DAA treatments.

Antimalarial drugs play an important role in the control and treatment of malaria, a deadly disease caused by the protozoan parasite Plasmodium spp. The development of novel antimalarial agents effective against drug-resistant malarial parasites is urgently needed. The novel derivatives, SKM13-MeO and SKM13-F, were designed based on an SKM13 template by replacing the phenyl group with electron-donating (-OMe) or electron-withdrawing groups (-F), respectively, to reverse the electron density. A colorimetric assay was used to quantify cytotoxicity, and in vitro inhibition assays were performed on 3 different blood stages (ring, trophozoite, and schizonts) of P. falciparum 3D7 and the ring/mixed stage of D6 strain after synchronization. The in vitro cytotoxicity analysis showed that 2 new SKM13 derivatives reduced the cytotoxicity of the SKM13 template. SKM13 maintained the IC50 at the ring and trophozoite stages but not at the schizont stage. The IC50 values for both the trophozoite stage of P. falciparum 3D7 and ring/mixed stages of D6 demonstrated that 2 SKM13 derivatives had decreased antimalarial efficacy, particularly for the SKM13-F derivative. SKM13 may be comparably effective in ring and trophozoite, and electron-donating groups (-OMe) may be better maintain the antimalarial activity than electron-withdrawing groups (-F) in SKM13 modification.

The PlazMagik device is a dual-gas cold atmospheric plasma (CAP) system that was developed and used for skin rejuvenation and inflammation treatment. However, preclinical evaluation and optimization of plasma parameters are crucial for guaranteeing safety. Therefore, this study was performed to evaluate the safety of the PlazMagik device under multiple parameters with different gas resources (helium (He) and argon (Ar) gases) on pig dorsal skin. After application of PlazMagik to the pig’s dorsal skin, temperature and visual assessments were observed immediately and for up to 30 days. All clinical parameters, including body weight and blood serum biochemistry, along with histopathological analysis (H&E, MT, VB, NBTC staining), were monitored pre-application and at 1, 7, 15, and 30 days post-application of the plasma device. Our results confirmed the safety of the machine at low-output energy settings, which showed gentle skin exfoliation but no tissue damage, while high-output settings led to the skin erosion effect, then developing erythema and coagulation. Ar gas resulted in more significant heat production and pathological changes than He under identical conditions. These findings emphasize the importance of the preclinical evaluation of the energy settings and gas selection on optimizing CAP system performance for safe clinical applications and appropriate application purposes.